Quick Answer
Dyne Therapeutics, Inc. reported R&D Expense of $398.33 million for fiscal year 2025.
Dyne Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $398.33M | +41.6% |
| 2024 | $281.41M | +33.5% |
| 2023 | $210.76M | +47.6% |
| 2022 | $142.76M | +17.7% |
| 2021 | $121.31M | +168.4% |
| 2020 | $45.20M | +309.4% |
| 2019 | $11.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $97.22M | +4.8% | -2.0% |
| June 30, 2025 | $99.24M | +59.4% | -6.8% |
| March 31, 2025 | $106.45M | +139.0% | +14.7% |
| September 30, 2024 | $92.80M | +68.0% | +49.0% |
| June 30, 2024 | $62.26M | +5.3% | +39.8% |
| March 31, 2024 | $44.54M | +18.7% | -19.4% |
| September 30, 2023 | $55.25M | +59.4% | -6.6% |
| June 30, 2023 | $59.13M | +26.7% | +57.5% |
- Dyne Therapeutics, Inc. showed an increase of +41.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Dyne Therapeutics, Inc.’s r&d expense has grown by 3508.1% (from $11.04 million to $398.33 million).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: